Prohibition Partners key insights from the European Canna
Conor O’Brien, Prohibition Partners
9th April 2021
Prohibition Partners explore the key insights from the European Cannabis Report: 6th Edition, providing detailed analyses on all aspects of the burgeoning industry from patient access and regulatory change to commercial opportunities and risks.
As detailed in the latest European Cannabis Report, 2020 was a significant year for medical cannabis in Europe in terms of patient access and regulatory and commercial progress. Despite the delays caused by COVID-19, Prohibition Partners estimate that 60,000 patients accessed medical cannabis on the continent for the first time during the year, bringing the total number of active patients to 185,000.
- Prohibition Partners estimate that the European cannabis market will be worth €403.4 million by the end of 2021 and will grow at a compound annual growth rate (CAGR) of 67.4% from 2021 to reach €3.2 billion by 2025.
- By the end of the forecast period, we expect several nations to introduce legal access to adult-use cannabis including the Netherlands, Switzerland, Germany and others. These sales could be worth over €500 million by 2025.
- Germany will constitute over half of the European market until 2024 and will be worth over €840 million by the end of the forecast period. By 2025, large countries like France and the UK will have developed their patient access considerably and will represent a significant share of the European market.
For full article:
https://prohibitionpartners.com/2021/04/09/key-insights-from-the-european-cannabis-report-6th-edition/#:~:text=Prohibition%20Partners%20estimate%20that%20the,%E2%82%AC3.2%20billion%20by%202025. eom
momo